High‐dose colchicine vs placebo
Total adverse events · acute gout
High‐dose colchicine may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 3.21 [2.01, 5.11]2 studies · 124 participantsLow
Findings
What do systematic reviews say?
40 questions · 40 findings · 21 reviews · Musculoskeletal
No studies found 5 · 12.5%GRADE not reported 0 · 0%Very low 8 · 20%Low 18 · 45%Moderate 7 · 17.5%High 2 · 5%
High‐dose vs low‐dose colchicine
Total adverse events · acute gout
High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).
1 finding from 1 review
- RR 2.11 [1.51, 2.95]1 study · 126 participantsLow
Low‐dose colchicine vs placebo
Total adverse events · acute gout
Low‐dose colchicine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.32 [0.68, 2.56]1 study · 103 participantsLow
Monthly pegloticase vs placebo
Total adverse events · participants with tophi in gout
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.05 [0.98, 1.14]1 study · 127 participantsModerate
Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED
Total adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
1 finding from 1 review
- RR 1.12 [0.96, 1.32]1 study · 129 participantsLow
Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS
Total adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
- RR 1.19 [1, 1.41]1 study · 67 participantsLow
Pegloticase every two weeks (biweekly) vs placebo
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.99 [0.91, 1.07]1 study · 128 participantsModerate
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors
Total adverse events · acute gout
Non‐selective NSAIDs probably leads to higher total adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
- RR 1.94 [1.36, 2.78]Studies not reportedModerate
NSAIDs vs glucocorticoids
Total adverse events · acute gout
NSAIDs probably leads to higher total adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
- RR 1.62 [1.03, 2.55]Studies not reportedModerate
NSAIDs vs placebo
Total adverse events · acute gout
NSAIDs showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.2 [0.01, 3.85]Studies not reportedLow
Vitamin C vs allopurinol
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
- no estimate extracted1 study · 40 participantsLow
Benzbromarone vs probenecid
Total adverse events · people with chronic gout
Benzbromarone may leads to lower total adverse events compared with probenecid (low certainty).
1 finding from 1 review
- RR 0.43 [0.25, 0.74]2 studies · 129 participantsLow
Benzbromarone vs allopurinol
Total adverse events · people with chronic gout
Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).
1 finding from 1 review
- RR 3 [0.64, 14.16]1 study · 55 participantsLow
Nefopam 60 mg tds vs placebo
Total adverse events · patients with pain management in rheumatoid arthritis
Nefopam 60 mg tds may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 4.11 [1.58, 10.69]2 studies · 104 participantsLow
Oromucosal cannabis (Sativex) vs placebo
Total adverse events · patients with pain management in rheumatoid arthritis
Oromucosal cannabis (Sativex) may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.82 [1.1, 3]1 study · 58 participantsLow
Skim milk enriched with GMP/G600 vs skim milk & lactose powder
Total adverse eventsd · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in total adverse eventsd compared with skim milk, plus lactose powder (low certainty).
1 finding from 1 review
- RR 0.97 [0.66, 1.45]1 study · 120 participantsLow
Intervention not reported
Total adverse events1 · people following primary uncemented THA
The review found no eligible studies for this question.
1 finding from 1 review
- Assistive devices, hip precautions, environmental modifications and training to prevent dislocation and improve… 2016 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Adverse events (total): · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments
It is very uncertain whether the intervention changes adverse events (total): (very low certainty).
1 finding from 1 review
- Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy 2020 · Cochrane Headline outcomes onlyRR 0.5 [0.14, 1.74]1 study · 42 participantsVery low
Intervention not reported
Total adverse events Last · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in total adverse events Last (low certainty).
1 finding from 1 review
- Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears) 2022 · Cochrane Headline outcomes onlyRR 1.15 [0.78, 1.7]9 studies · 1326 participantsLow
Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic
Total serious adverse events · patients with rheumatoid arthritis
Abatacept (2 and 10mg/kg) + DMARDs/biologic showed no clear difference in total serious adverse events compared with placebo + DMARDs/biologic (moderate certainty).
1 finding from 1 review
- RR 1.05 [0.87, 1.28]6 studies · 3151 participantsModerate